Plaque Induced GingivitisPhase 3NCT05787600
Anti-inflammatory and Anti-plaque Efficacies of Mouth Rinse Containing Hyaluronic Acid and Hydrogen Peroxide
A Phase 3 study testing Perhyal rinse and Chlorhexidine mouthwash in people with Plaque Induced Gingivitis and Mouth Diseases, run by University of Baghdad at 1 site in Iraq.
Trial summary
The goal of this clinical trial is to test efficiency of using mouth rinse containing (H2O2 and HA) over a period of two weeks to control on gingival inflammation and plaque accumulation through measuring the clinical periodontal parameters (Gingival Index (GI), Bleeding on probing (BOP) and modified Quigley-Hein… Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Plaque Induced Gingivitis, Mouth Diseases, Bleeding Gum
- What is being tested?
- Perhyal rinse and Chlorhexidine mouthwash
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 54 participants
- Where
- 1 siteIraq
- Study dates
- 3 Mar 2023to 1 May 2023
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subjects aged ≥ 18 years-old.
- participants who were apparently systemically healthy.
- Presence of ≥ 20 teeth.
- Patients with generalized gingivitis (having >30% bleeding sites with no PPD >3 mm, intact periodontium and no loss of periodontal attachment .
- Patients without presence of supra- or subgingival calculus
Who cannot join
- Patients who refuse to write an informed consent form.
- Extensive untreated dental caries and diseases of hard and soft palate.
- Those having periodontitis.
- Ongoing orthodontic treatment.
- History of antibiotics intake within the past 3 months.
- Pregnant or intended to and lactating mother.
Show all 10Show fewer
- Smoker or alcoholism
- Using mouthwash within past one month.
- Those with a recent tooth extraction.
- Those having a history of hypersensitivity to any product used in the present study.
Trial locations and contacts
1 site in 1 country.
Iraq1 site
University of Baghdad\ College of Dentistry
Baghdad, Bab Al-Moadham, 10047
About this study
Official title: The Anti-inflammatory and Anti-plaque Efficacies of Mouth Rinse Containing Hyaluronic Acid and Hydrogen Peroxide in the Management of Dental Biofilm-induced Gingivitis: a 14 Days Randomized Clinical Trial
The goal of this clinical trial is to test efficiency of using mouth rinse containing (H2O2 and HA) over a period of two weeks to control on gingival inflammation and plaque accumulation through measuring the clinical periodontal parameters (Gingival Index (GI), Bleeding on probing (BOP) and modified Quigley-Hein Plaque Index (mQHPI ) in comparison with Chlorhexidine (CHX) and placebo mouth rinses in patients with biofilm induced gingivitis.
Objectives:
- Evaluate the clinical efficiency of using mouth rinse containing (H2O2 and HA) over a period of 14 days to control on gingival inflammation and plaque accumulation through measuring the clinical periodontal parameters (Gingival Index, Bleeding on probing and modified Quigley-Hein Plaque Index in comparison with Chlorhexidine and placebo mouth rinses in patients with biofilm induced gingivitis.
- Measuring levels of salivary cytokines, Interleukin 1 beta (IL-1B) and Interleukin 6 (IL-6) at baseline visit before using mouth rinse and after 14 days of using the mouth rinse containing H2O2 and HA compared to chlorhexidine and placebo mouth rinses.
- Evaluate subjects' perception of a mouth rinse (H2O2 and HA), CHX and placebo mouth rinses after 14 days from using three mouth rinse
Read the detailed description
54 subjects will be enrolled, who show with generalized gingivitis (having >30% bleeding sites with no PPD >3 mm, intact periodontium and no loss of periodontal attachment), caused by accumulation of plaque.
A double-blind, randomized parallel 3-arms clinical trial include using the following mouth rinses, 0.12% CHX (KIN Gingival, KIN, Barcelona, Spain) as positive-control , distilled water (placebo, nonactive control) with food additives (to blind the subjects and examiner) and Perhyal rinse (BMG Pharma, Milan, Italy ) containing has H2O2 (1,80%) and HA (0,10%) with the remaining part being water (97,3%) and inert additives as active ingredients, will be used as test interventions. The mouthwashes will be contained in identical opaque bottles that were randomly given sequential letters codes (A, B and C ) by a another subject who will not involved in the clinical investigation. This ensured the double blindness of both the participant and examiner during the clinical trial. Decoding will performed after the end of the study.
Randomization will be performed by the examiner for enrollment patient in 3 groups. Each group will be assigned a letter (A, B or C) corresponding to the intervention used. Random numbers were generated and used to re-sort the order of the groups and participants (n=54), who will distributing into designated groups, each group received a similar number of subjects (n=18) with a 1:1:1 allocation, by using a Microsoft Excel random table (Microsoft Office 2016, Microsoft Corporation, USA). Then, coded bottles with the interventions will be delivered to the participants together with instructions for use. The participants will be asked to rinse with 10 ml of undiluted.
mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. Discontinuation of the mouthwash will be advised in cases of any allergic reaction. All participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE®, Colgate-Palmolive, NY, USA). No modifications to the participants' tooth brushing technique will be permitted.
In baseline visit at the beginning,
Saliva collection for IL-1β and IL-6 measurement then clinical periodontal parameters examination starting with gingival index (Loe and Silness in 1963) designed to assess the severity and quality of gingival inflammation in an individual or population. The gingival inflammation is assessed on the basis of color, consistency and bleeding on probing. A periodontal probe will be runned along the gingival margin. The gingiva surrounding the tooth is assessed at four sites: mesio-facial papilla, facial marginal gingiva, disto-facial papilla and lingual marginal gingiva.
Followed by dryness and wait then measurement of BOP for the six surfaces of all teeth except wisdom teeth through gently inserting the periodontal probe to the depth of the gingival sulcus then removed coronally and waited for 30 s to observe the presence of bleeding (0=no bleeding, 1=presence of bleeding)
Then finally followed by the Modified Quigley Hein Plaque Index with Fluorescein disclosing tablets. In the (mQHPI) the data had been recorded from labial/buccal and lingual/palatal surfaces of each disclosed tooth except wisdom teeth and any teeth had filling surface.
The distance from the gingival margin to the edge of the disclosed area measured to the nearest 0.5 mm using a calibrated periodontal probe and the scores registered according to record form of mQHPI for each participant. The mean of mQHPI for each participant had been calculated by collecting the scores over the total number of surfaces examined.
First visit after 14 days, from the baseline visit.
Saliva collection and clinical periodontal parameters scoring (GI, BOP ,mQHP) will be performed again as described at baseline visit. The mouthwash bottles will be retrieved, and the remaining volume will be determining to further evaluate the compliance with mouth rinsing.
(the total volume/bottle for two weeks will be 280 ml).
For the purpose of self-assessment, a visual analog scale (VAS)- score based questionnaire was filled out by each participant at the end of the trial to evaluate the intervention. The questionnaire and method of data interpretation were adopted and modified from a previous study.
- Being tested
- Perhyal rinse, Chlorhexidine mouthwash, Placebo
- Keywords
- Gingivitis, Plaque, Hyaluronic acid, hydrogen peroxide
- Medical subject headings
- Mouth Diseases, Gingival Hemorrhage, Periodontal Diseases, Gingivitis, Plaque, Amyloid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Perhyal rinseDrug
Also called BMG0703
Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Chlorhexidine mouthwashDrug
Also called Chlorhexidine 0.12%
Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
PlaceboDrug
Also called Placebo product
Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
| Study group | Role | What they receive |
|---|---|---|
| Perhyal rinse | Experimental | Participants will be given the test interventions,Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. Receives: Drug: Perhyal rinse |
| Chlorhexidine 0.12% | Active comparator | Participants will be given the positive-control, Chlorhexidine 0.12%, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. Receives: Drug: Chlorhexidine mouthwash |
| Placebo Product | Placebo comparator | Participants will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Gingival index
Subjects will undergo the measurement of gingival index according to Loe \& Silness, designed to assess the severity and quality of gingival inflammation in an individual or population. The gingival inflammation is assessed on the basis of color, consistency and bleeding on probing. The gingiva surrounding the tooth is assessed at four sites: mesio-facial papilla, facial marginal gingiva, disto-facial papilla and lingual marginal gingiva. Data will be collected based on four possible clinical conditions:
0=Normal gingiva1=Mild Inflammation-Slight change in color, Slight odema. No bleeding on probing2=Moderate inflammation-redness,odema and glazing. Bleeding on probing 3=Sever inflammation-marked redness and edema.Ulceration.Tendency to spontaneous bleeding.
Measured: 0, 14 days
Secondary outcomes (4)
Mean amount plaque between different comparators.
Mean amount plaque between different comparators as anti-plaque agent after rinsing with different comparators using means of modified quigely hein plaque index[ Turesky ,1970]
Measured: 14 days
Assessment of the interventions by the participants through answering specially designed
All subjects received a questionnaire using a visual analog scale(VAS) designed to evaluate their attitudes with regard to the product used. Subjects marked a point on a 10-cm-long uncalibrated line with the negative extreme response (0) at the left end and the positive extreme response (10) at the right end.
Measured: 14 days
Mean relative changes in Interleukin 1 beta and Interleukin 6 levels in salivary Fluid.
Mean relative changes in Interleukin 1 beta and Interleukin 6 levels in salivary fluid after rinsing with different comparators from baseline at 14 days.
Measured: 14 days
Changes in BOP score
For recording BOP score, the periodontal probe was inserted with gentle force into the sulcus/pocket until minimal resistance was felt. The probing force presumably was ranging between 20 to 25g. The examination started from the distal surface of the right upper 7 moving mesially to measure all the existing teeth. For each tooth, 6 surfaces were examined; the surface that displayed bleeding on probing was scored 1 and the surface with no bleeding was scored 0
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2023
- Study start3 Mar 2023
- Primary completion20 Apr 2023
- Study completion1 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Plaque Induced GingivitisStudies of the same condition, open and under way.
- More trials run by University of BaghdadThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 54 subjects with plaque induced gingivitis, caused by accumulation of plaque, will be selected and enrolled in this study. Subsequently, subjects will be equally divided and randomly allocated for three groups, each group received a similar number of subjects (n=18) with a 1:1:1 allocation.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Baghdad
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Hashim Alyasari, University of Baghdad
- Investigators
- Ahmed alyasari, B.D.S, Principal investigator, University of Baghdad
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05787600
- Sponsor's protocol ID
- 748622
- Status last verified
- Oct 2023
- First submitted
- 3 Mar 2023
- Last updated
- 4 Oct 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Anti-inflammatory and Anti-plaque Efficacies of Mouth Rinse Containing Hyaluronic Acid and Hydrogen Peroxide in the Management of Dental Biofilm-induced Gingivitis: a 14 Days Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT05787600
- Acronym / sponsor ID
- 748622
- Keywords
- Gingivitis, Plaque, Hyaluronic acid, hydrogen peroxide
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- University of BaghdadUniversity, hospital or other
- Study start
- 3 Mar 2023 (actual)
- Primary completion
- 20 Apr 2023 (actual)
- Study completion
- 1 May 2023 (actual)
- First posted
- 28 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test efficiency of using mouth rinse containing (H2O2 and HA) over a period of two weeks to control on gingival inflammation and plaque accumulation through measuring the clinical periodontal parameters (Gingival Index (GI), Bleeding on probing (BOP) and modified Quigley-Hein Plaque Index (mQHPI ) in comparison with Chlorhexidine (CHX) and placebo mouth rinses in patients with biofilm induced gingivitis.
Objectives:
- Evaluate the clinical efficiency of using mouth rinse containing (H2O2 and HA) over a period of 14 days to control on gingival inflammation and plaque accumulation through measuring the clinical periodontal parameters (Gingival Index, Bleeding on probing and modified Quigley-Hein Plaque Index in comparison with Chlorhexidine and placebo mouth rinses in patients with biofilm induced gingivitis.
- Measuring levels of salivary cytokines, Interleukin 1 beta (IL-1B) and Interleukin 6 (IL-6) at baseline visit before using mouth rinse and after 14 days of using the mouth rinse containing H2O2 and HA compared to chlorhexidine and placebo mouth rinses.
- Evaluate subjects' perception of a mouth rinse (H2O2 and HA), CHX and placebo mouth rinses after 14 days from using three mouth rinse
Detailed description
54 subjects will be enrolled, who show with generalized gingivitis (having >30% bleeding sites with no PPD >3 mm, intact periodontium and no loss of periodontal attachment), caused by accumulation of plaque.
A double-blind, randomized parallel 3-arms clinical trial include using the following mouth rinses, 0.12% CHX (KIN Gingival, KIN, Barcelona, Spain) as positive-control , distilled water (placebo, nonactive control) with food additives (to blind the subjects and examiner) and Perhyal rinse (BMG Pharma, Milan, Italy ) containing has H2O2 (1,80%) and HA (0,10%) with the remaining part being water (97,3%) and inert additives as active ingredients, will be used as test interventions. The mouthwashes will be contained in identical opaque bottles that were randomly given sequential letters codes (A, B and C ) by a another subject who will not involved in the clinical investigation. This ensured the double blindness of both the participant and examiner during the clinical trial. Decoding will performed after the end of the study.
Randomization will be performed by the examiner for enrollment patient in 3 groups. Each group will be assigned a letter (A, B or C) corresponding to the intervention used. Random numbers were generated and used to re-sort the order of the groups and participants (n=54), who will distributing into designated groups, each group received a similar number of subjects (n=18) with a 1:1:1 allocation, by using a Microsoft Excel random table (Microsoft Office 2016, Microsoft Corporation, USA). Then, coded bottles with the interventions will be delivered to the participants together with instructions for use. The participants will be asked to rinse with 10 ml of undiluted.
mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. Discontinuation of the mouthwash will be advised in cases of any allergic reaction. All participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE®, Colgate-Palmolive, NY, USA). No modifications to the participants' tooth brushing technique will be permitted.
In baseline visit at the beginning,
Saliva collection for IL-1β and IL-6 measurement then clinical periodontal parameters examination starting with gingival index (Loe and Silness in 1963) designed to assess the severity and quality of gingival inflammation in an individual or population. The gingival inflammation is assessed on the basis of color, consistency and bleeding on probing. A periodontal probe will be runned along the gingival margin. The gingiva surrounding the tooth is assessed at four sites: mesio-facial papilla, facial marginal gingiva, disto-facial papilla and lingual marginal gingiva.
Followed by dryness and wait then measurement of BOP for the six surfaces of all teeth except wisdom teeth through gently inserting the periodontal probe to the depth of the gingival sulcus then removed coronally and waited for 30 s to observe the presence of bleeding (0=no bleeding, 1=presence of bleeding)
Then finally followed by the Modified Quigley Hein Plaque Index with Fluorescein disclosing tablets. In the (mQHPI) the data had been recorded from labial/buccal and lingual/palatal surfaces of each disclosed tooth except wisdom teeth and any teeth had filling surface.
The distance from the gingival margin to the edge of the disclosed area measured to the nearest 0.5 mm using a calibrated periodontal probe and the scores registered according to record form of mQHPI for each participant. The mean of mQHPI for each participant had been calculated by collecting the scores over the total number of surfaces examined.
First visit after 14 days, from the baseline visit.
Saliva collection and clinical periodontal parameters scoring (GI, BOP ,mQHP) will be performed again as described at baseline visit. The mouthwash bottles will be retrieved, and the remaining volume will be determining to further evaluate the compliance with mouth rinsing.
(the total volume/bottle for two weeks will be 280 ml).
For the purpose of self-assessment, a visual analog scale (VAS)- score based questionnaire was filled out by each participant at the end of the trial to evaluate the intervention. The questionnaire and method of data interpretation were adopted and modified from a previous study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
- Model description
- 54 subjects with plaque induced gingivitis, caused by accumulation of plaque, will be selected and enrolled in this study. Subsequently, subjects will be equally divided and randomly allocated for three groups, each group received a similar number of subjects (n=18) with a 1:1:1 allocation.
| Arm | Type | Receives |
|---|---|---|
| Perhyal rinse | Experimental | Drug: Perhyal rinseParticipants will be given the test interventions,Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. |
| Chlorhexidine 0.12% | Active comparator | Drug: Chlorhexidine mouthwashParticipants will be given the positive-control, Chlorhexidine 0.12%, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. |
| Placebo Product | Placebo comparator | Drug: PlaceboParticipants will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Subjects aged ≥ 18 years-old.
- participants who were apparently systemically healthy.
- Presence of ≥ 20 teeth.
- Patients with generalized gingivitis (having >30% bleeding sites with no PPD >3 mm, intact periodontium and no loss of periodontal attachment .
- Patients without presence of supra- or subgingival calculus
Key exclusion criteria (10 listed)
- Patients who refuse to write an informed consent form.
- Extensive untreated dental caries and diseases of hard and soft palate.
- Those having periodontitis.
- Ongoing orthodontic treatment.
- History of antibiotics intake within the past 3 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Perhyal rinseAlso: BMG0703Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days. | Drug | Perhyal rinse |
| Chlorhexidine mouthwashAlso: Chlorhexidine 0.12%Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days. | Drug | Chlorhexidine 0.12% |
| PlaceboAlso: Placebo productSubjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days. | Drug | Placebo Product |
Primary outcome
Change in Gingival index
Time frame: 0, 14 days
Subjects will undergo the measurement of gingival index according to Loe \& Silness, designed to assess the severity and quality of gingival inflammation in an individual or population. The gingival inflammation is assessed on the basis of color, consistency and bleeding on probing. The gingiva surrounding the tooth is assessed at four sites: mesio-facial papilla, facial marginal gingiva, disto-facial papilla and lingual marginal gingiva. Data will be collected based on four possible clinical conditions: 0=Normal gingiva1=Mild Inflammation-Slight change in color, Slight odema. No bleeding on probing2=Moderate inflammation-redness,odema and glazing. Bleeding on probing 3=Sever inflammation-marked redness and edema.Ulceration.Tendency to spontaneous bleeding.
4 secondary outcomes
Mean amount plaque between different comparators.
Time frame: 14 days
Assessment of the interventions by the participants through answering specially designed
Time frame: 14 days
Mean relative changes in Interleukin 1 beta and Interleukin 6 levels in salivary Fluid.
Time frame: 14 days
Changes in BOP score
Time frame: 14 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Oct 2023.
Related trials for Plaque Induced Gingivitis
Not yet recruitingPhase 2
Efficacy of Thymus Vulgaris Mouthwash in the Management of Biofilm-Induced Gingivitis
Plaque-Induced Gingivitis
Not yet recruiting
Effectiveness of Oil Pulling Using Oils in Comparison With Mouthwash for Gingivitis
Gingivitis
Active, not recruitingObservational study
Comparison of Saliva Characteristics and Oral Health in Pregnant and Non-pregnant Women
Plaque Induced Gingivitis
Not yet recruiting
Individualized Management of Plaque-Related Gingival Inflammation in Routine Dental Practice
Plaque-Induced Gingivitis
Not yet recruitingPhase 1
Taste Acceptance and Effectiveness of Hyaluronic Acid and Chlorhexidine Mouthwashes in Children With Gingivitis
Plaque Induced Gingival Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ahmed alyasari, B.D.S principal investigator
University of Baghdad
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Perhyal rinse and Chlorhexidine mouthwash in people with Plaque Induced Gingivitis and Mouth Diseases, run by University of Baghdad at 1 site in Iraq.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Gingival index (time frame: 0, 14 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Oct 2023.